Palvella Therapeutics (PVLA) News
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
142.85-2.92 (-2.00%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PVLA news summary
We found 11 recent headlines mentioning Palvella Therapeutics (PVLA): 3 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, PVLA is down 2.00% at $142.85. The most recent story, "Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Palvella Therapeutics headlines
- Palvella Therapeutics Announces QTORIN™ Docetaxel, a New QTORIN™ Program for the Treatment of Extramammary Paget’s Disease (EMPD)EMPD is a serious, rare, and life-threatening genital and perianal skin cancerGlobeNewswire
- Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ ProgramThird product candidate from Palvella’s QTORIN™ platform to be announcedGlobeNewswire
- Leerink Partners Initiates Coverage of Palvella Therapeutics at OutperformFintel reports that on November 16, 2026, Leerink Partners initiated coverage of Palvella Therapeutics (NASDAQGM:PVLA) (DB:PI6) with a Outperform recommendation.Nasdaq
- Palvella Therapeutics GAAP EPS of -$1.70 beats by $0.07Seeking Alpha
- Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateFDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027GlobeNewswire
- Palvella Therapeutics to Participate in the Stifel 2026 Healthcare ConferenceWAYNE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…GlobeNewswire
- Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date SetQTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and…GlobeNewswire
- Why is Palvella Therapeutics stock sliding 3% today?Investing.com
- Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePhase 3 SELVA Pediatric Analyses Highlight Improvements in Overall Disease Severity and a Blinded Combined Score of Lesion Height, Vesicle Appearance, and Leaking/BleedingGlobeNewswire
- Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceWAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and…GlobeNewswire
- Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ RapamycinGlobeNewswire